- Home
- SENEB vs CDNA Comparison
SENEB vs CDNA Comparison
Compare SENEB & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEB
- CDNA
- Stock Information
- Founded
- SENEB 1949
- CDNA 1998
- Country
- SENEB United States
- CDNA United States
- Employees
- SENEB N/A
- CDNA N/A
- Industry
- SENEB Packaged Foods
- CDNA Medical Specialities
- Sector
- SENEB Consumer Staples
- CDNA Health Care
- Exchange
- SENEB Nasdaq
- CDNA Nasdaq
- Market Cap
- SENEB 720.7M
- CDNA 712.2M
- IPO Year
- SENEB N/A
- CDNA 2014
- Fundamental
- Price
- SENEB $110.57
- CDNA $15.66
- Analyst Decision
- SENEB
- CDNA Buy
- Analyst Count
- SENEB 0
- CDNA 7
- Target Price
- SENEB N/A
- CDNA $26.00
- AVG Volume (30 Days)
- SENEB 107.0
- CDNA 1.2M
- Earning Date
- SENEB 11-05-2025
- CDNA 11-04-2025
- Dividend Yield
- SENEB N/A
- CDNA N/A
- EPS Growth
- SENEB 47.84
- CDNA N/A
- EPS
- SENEB 8.62
- CDNA 1.22
- Revenue
- SENEB $1,606,175,000.00
- CDNA $357,998,000.00
- Revenue This Year
- SENEB N/A
- CDNA $12.73
- Revenue Next Year
- SENEB N/A
- CDNA $11.90
- P/E Ratio
- SENEB $12.39
- CDNA $12.86
- Revenue Growth
- SENEB 8.33
- CDNA 14.46
- 52 Week Low
- SENEB $63.00
- CDNA $10.96
- 52 Week High
- SENEB $116.97
- CDNA $26.37
- Technical
- Relative Strength Index (RSI)
- SENEB 62.42
- CDNA 55.09
- Support Level
- SENEB $110.96
- CDNA $14.27
- Resistance Level
- SENEB $112.30
- CDNA $16.60
- Average True Range (ATR)
- SENEB 0.24
- CDNA 0.88
- MACD
- SENEB -0.60
- CDNA 0.06
- Stochastic Oscillator
- SENEB 69.01
- CDNA 58.17
About SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.